Abstract
Due to the limited proliferation capacity of cardiac cells, cell replacement therapy has been proposed to restore cardiac function in patients suffering from ischemic heart disease and congestive heart failure. However, this approach is challenged by an insufficient supply of appropriate cells. Because of their apparent indefinite replicative capacity and their cardiac differentiation potential, human embryonic stem cells (hESCs) are potential candidates as sources of cells for cell replacement therapy. Significant progress has been made in improving culture conditions of undifferentiated hESCs, and using various methods, several laboratories have reported the generation of contracting cardiomyocytes from hESCs in vitro. Application of these cardiomyocytes to the clinic, however, still requires substantial experimentation to show that 1) they are functional in vitro; 2) they are efficacious in animal models of cardiac injury and disease; 3) they are safe and effective in human conditions, and 4) a sufficient amount of cardiomyocytes with expected characteristics can be generated in a reproducible manner. Here we review and discuss current findings on growth and differentiation of hESCs, and on characterization, enrichment and transplantation of hESC-derived cardiomyocytes.
Keywords: Human embryonic stem cells, cardiomyocytes, cell culture, differentiation, and transplantation
Current Stem Cell Research & Therapy
Title: Growth and Differentiation of Human Embryonic Stem Cells for Cardiac Cell Replacement Therapy
Volume: 1 Issue: 2
Author(s): Chunhui Xu, Jane Lebkowski and Joseph D. Gold
Affiliation:
Keywords: Human embryonic stem cells, cardiomyocytes, cell culture, differentiation, and transplantation
Abstract: Due to the limited proliferation capacity of cardiac cells, cell replacement therapy has been proposed to restore cardiac function in patients suffering from ischemic heart disease and congestive heart failure. However, this approach is challenged by an insufficient supply of appropriate cells. Because of their apparent indefinite replicative capacity and their cardiac differentiation potential, human embryonic stem cells (hESCs) are potential candidates as sources of cells for cell replacement therapy. Significant progress has been made in improving culture conditions of undifferentiated hESCs, and using various methods, several laboratories have reported the generation of contracting cardiomyocytes from hESCs in vitro. Application of these cardiomyocytes to the clinic, however, still requires substantial experimentation to show that 1) they are functional in vitro; 2) they are efficacious in animal models of cardiac injury and disease; 3) they are safe and effective in human conditions, and 4) a sufficient amount of cardiomyocytes with expected characteristics can be generated in a reproducible manner. Here we review and discuss current findings on growth and differentiation of hESCs, and on characterization, enrichment and transplantation of hESC-derived cardiomyocytes.
Export Options
About this article
Cite this article as:
Xu Chunhui, Lebkowski Jane and Gold D. Joseph, Growth and Differentiation of Human Embryonic Stem Cells for Cardiac Cell Replacement Therapy, Current Stem Cell Research & Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488806776956931
DOI https://dx.doi.org/10.2174/157488806776956931 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Editorial [Hot Topic: The Medicinal Chemistry of Agents Targeting the Nuclear Hormone Receptor Guest Editor: John Regan ]
Current Topics in Medicinal Chemistry Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis Therapeutic Proteins and Nanotechnology: Immune Response and Stealth Bioengineered Constructs
Current Drug Metabolism The Role of Combined Assessment of Defense Against Oxidative Stress and Inflammation in the Evaluation of Peripheral Arterial Disease
Current Molecular Medicine Pindolol Augmentation of Antidepressant Response
Current Drug Targets New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Evaluation and Comparative Correlation of Abdominal Fat Related Parameters in Obese and Non-obese Groups Using Computed Tomography
Current Medical Imaging Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design <i>Panax notoginseng</i> Saponins Promote Cell Death and Chemosensitivity in Pancreatic Cancer through the Apoptosis and Autophagy Pathways
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Recent Advances in Cancer Chemotherapy-Part I (Guest Editor: Diwan S. Rawat)]
Anti-Cancer Agents in Medicinal Chemistry Relationship between SNP rs1764391 and Susceptibility, Risk Factors, Gene-environment Interactions of Acute Myocardial Infarction in Guangxi Han Chinese Population
Current Pharmaceutical Biotechnology Emerging Role of Antioxidants in the Protection of Uveitis Complications
Current Medicinal Chemistry Incretin-Based Therapies in Patients with Type 2 Diabetes
Current Drug Therapy Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Effects of Different Types of Physical Exercise on the Perceived Quality of Life in Active Elderly
CNS & Neurological Disorders - Drug Targets Novel Oral Anticoagulants in the Treatment of Acute Coronary Syndromes: Is there any Room for New Anticoagulants?
Current Clinical Pharmacology Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung Injury
Current Pharmaceutical Design